Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,755 INR | -0.72% | +4.85% | +6.87% |
May. 14 | Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 | MT |
May. 13 | Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 65 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.87% | 2.76B | B- | ||
-22.94% | 7.77B | B+ | ||
+77.32% | 4.51B | C+ | ||
-2.28% | 2.67B | - | ||
-47.96% | 2.09B | B- | ||
-15.91% | 1.72B | C- | ||
-19.62% | 1.49B | A- | ||
+18.29% | 1.22B | B+ | ||
-44.77% | 1.12B | C+ | ||
+20.68% | 1.05B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LALPATHLAB Stock
- Ratings Dr. Lal PathLabs Limited